Last reviewed · How we verify
Moderate to Severe Ulcerative Colitis
Approved treatments
- Induction- PF-06480605 450 mg SC Q4W · Pfizer
PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions. - tumor necrosis factor inhibitors (TNFi) · Pfizer
- Etrasimod · Pfizer
Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes. - TNF Inhibitor · Pfizer
- Chronic- PF-06480605 50 mg SC Q4W · Pfizer
- Velsipity · Pfizer Inc.
Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks. - Induction- PF-06480605 150 mg SC Q4W · Pfizer
PF-06480605 is a medication for the treatment of inflammatory conditions, administered via subcutaneous injection every 4 weeks.
Clinical guidelines
- FDA label — any
VELSIPITY is indicated for the treatment of moderately to severely active ulcerative colitis in adults. - FDA label — any
VELSIPITY is indicated for the treatment of moderately to severely active Crohn's disease in adults. - FDA label — any
VELSIPITY is indicated for the treatment of moderately to severely active ulcerative colitis in adults. - FDA label — any
VELSIPITY is indicated for the treatment of moderately to severely active Crohn's disease in adults.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to Severe Ulcerative Colitis patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to Severe Ulcerative Colitis treatment landscape brief
- Moderate to Severe Ulcerative Colitis treatment updates RSS
Frequently asked questions about Moderate to Severe Ulcerative Colitis
What drugs treat Moderate to Severe Ulcerative Colitis?
Tracked treatments include Induction- PF-06480605 450 mg SC Q4W, tumor necrosis factor inhibitors (TNFi), Etrasimod, TNF Inhibitor, Chronic- PF-06480605 50 mg SC Q4W, Velsipity, Induction- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W.
What is the treatment for Moderate to Severe Ulcerative Colitis?
Standard treatment for Moderate to Severe Ulcerative Colitis includes Induction- PF-06480605 450 mg SC Q4W, tumor necrosis factor inhibitors (TNFi), Etrasimod, TNF Inhibitor, Chronic- PF-06480605 50 mg SC Q4W. See the treatment landscape page for first-line, second-line and salvage options.
What are the treatment guidelines for Moderate to Severe Ulcerative Colitis?
FDA label publishes guidelines for Moderate to Severe Ulcerative Colitis. 4 guideline references tracked.
Related
- Treatment landscape: Moderate to Severe Ulcerative Colitis patent cliff · Moderate to Severe Ulcerative Colitis CI report
- Treatment: Induction- PF-06480605 450 mg SC Q4W · Pfizer
- Treatment: tumor necrosis factor inhibitors (TNFi) · Pfizer
- Treatment: Etrasimod · Pfizer
- Treatment: TNF Inhibitor · Pfizer
- Treatment: Chronic- PF-06480605 50 mg SC Q4W · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing